Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

ADC antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (27) ADC Cytotoxin (70) ADC Linker (718) Antibody-Drug Conjugates (ADCs) (42) Drug-Linker Conjugates for ADC (77) PROTAC-Linker Conjugates for PAC (3) Amino Acid Derivatives (1) Antifolate (2) Apoptosis (10) Bacterial (5) Bcl-2 Family (1) Btk (1) c-Met/HGFR (1) CD19 (1) CD22 (3) CD276/B7-H3 (1) DNA Alkylator/Crosslinker (15) DNA/RNA Synthesis (2) Drug Metabolite (2) E3 Ligase Ligand-Linker Conjugates (1) EGFR (12) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (3) FGFR (1) FLT3 (1) Glucocorticoid Receptor (5) IGF-1R (1) Integrin (1) Interleukin Related (2) Isotope-Labeled Compounds (5) Kinesin (1) Mesothelin (1) Microtubule/Tubulin (26) Mitochondrial Metabolism (1) NAMPT (4) Nectin-4 (1) Notch (1) PD-1/PD-L1 (2) PROTAC Linkers (208) PROTACs (2) STING (3) TAM Receptor (3) TNF Receptor (1) Toll-like Receptor (TLR) (1) Topoisomerase (29) TROP2 (5)
By Research Areas:	Cancer (977) Cardiovascular Disease (2) Infection (8) Inflammation/Immunology (39) Metabolic Disease (1)
Click Chemistry:	ADC Synthesis (236) TCO (15) DBCO (58) PROTAC Synthesis (55) Azide (81) BCN (21) Tetrazine (31) Alkynes (49)

1002

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

248

Click Chemistry

Targets Recommended: ADC Antibody ADC Linker ADC Cytotoxin Antibody-Drug Conjugates (ADCs) Drug-Linker Conjugates for ADC PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156897

Val-Cit-amide-Ph-Maytansine	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-amide-Ph-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs) .

HY-156896

Val-Cit-amide-Cbz-N(Me)-Maytansine	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-amide-Cbz-N(Me)-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs) .

HY-131955

Fmoc-aminooxy-PEG2-NH2	ADC Linker	Cancer
Fmoc-aminooxy-PEG2-NH2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-P99970

Lifastuzumab	ADC Antibody	Others
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity .

HY-P99285

Denintuzumab 1 Publications Verification hBU 12	ADC Antibody CD19	Others
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC *antibody) of antibody-drug conjugates to synthesize ADC*, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .

HY-P99352

Anetumab Anti-MSLN antibody	Mesothelin	Cancer
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor .

HY-P99042

Polatuzumab 1 Publications Verification	ADC Antibody	Cancer
Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b .

HY-P99016

Enfortumab	ADC Antibody Nectin-4	Cancer
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .

HY-156712

Depatuxizumab MMAE	Antibody-Drug Conjugates (ADCs)	Cancer
Depatuxizumab MMAE is an **antibody-drug conjugate (ADC)** comprising an anti EGFR monoclonal antibody (Depatuxizumab) and the cytotoxic agent Monomethyl auristatin E (MMAE). Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR .

HY-W019939

Hydroxy-PEG10-Boc	ADC Linker	Cancer
Hydroxy-PEG10-Boc is extacted from patent CN108707228 (example 0024) . Hydroxy-PEG10-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG10-Boc can be conjugated to Paclitaxel (HY-B0015) or docetaxel (HY-B0011) .

HY-132158

MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin	Drug-Linker Conjugates for ADC	Cancer
MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (compound 21a), a camptothecin payload, can be conjugated to a monoclonal antibody (mAb) for the synthesis of camptothecin **antibody-drug conjugate (ADC)** .

HY-400878

Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Mal	Glucocorticoid Receptor Drug-Linker Conjugates for ADC	Cancer
Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Mal, a glucocorticoid receptor agonist, is a drug-linker conjugate for ADC. Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Mal can be used to synthesize the anti-CD40 antibody agent conjugates (WO2019106608A1; example 9) .

HY-P99043

Rovalpituzumab	Notch	Cancer
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine . Rovalpituzumab has activity against small cell lung cancer (SCLC) .

HY-P99205

Glembatumumab	ADC Antibody	Cancer
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .

HY-128870

Mal-PEG2-VCP-Eribulin	Drug-Linker Conjugates for ADC	Cancer
Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates .

HY-P99740

Mirzotamab	CD276/B7-H3 ADC Antibody	Cancer
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .

HY-P99843

Datopotamab	TROP2 ADC Antibody	Cancer
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-P99229

Upifitamab 1 Publications Verification	ADC Antibody	Cancer
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for **antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b** and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer .

HY-W101718

Fmoc-N-(2-Boc-aminoethyl)-Gly-OH	Isotope-Labeled Compounds ADC Linker	Cancer
Fmoc-N-(2-Boc-aminoethyl)-Gly-OH is a Fmoc-protected glycine derivative that can be used in antibody agent coupling (ADC) synthesis. ADC consists of antibodies that are linked to ADC cytotoxins via ADC junctions[1].

HY-42146

BMPS	ADC Linker	Cancer
BMPS is a nonclaevable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-78932A

Dap-NE hydrochloride	ADC Linker	Cancer
Dap-NE hydrochloride is a dipeptide hydrochloride and a cleavable ADC Linker.Dap-NE hydrochloride can be used to connect Antibody and toxin molecules (Cytotoxin) to synthesize Antibody-Drug Conjugates (ADCs) .

HY-12448

SPDB	ADC Linker	Cancer
SPDB is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs) .

HY-126667

SC-Val-Cit-PAB	ADC Linker	Cancer
SC-Val-Cit-PAB is a cleavable ADC linker for antibody-drug conjugates (ADCs).

HY-129366

PDB-Pfp	ADC Linker	Cancer
PDB-Pfp is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-129368

SPDMV	ADC Linker	Cancer
SPDMV is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs) .

HY-129369

SPDMB	ADC Linker	Cancer
SPDMB is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs) .

HY-129373

SPDMV-sulfo	ADC Linker	Cancer
SPDMV-sulfo is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs).

HY-139441

DM21	Drug-Linker Conjugates for ADC	Cancer
DM21 is a conjugate of a cleavable ADC agent and a linker (ADC linker) used in the synthesis of antibody-drug conjugates (ADCs) .

HY-128970

Mp-polymer ester	ADC Linker	Cancer
Mp-polymer ester is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-129370

SPDB-sulfo	ADC Linker	Cancer
SPDB-sulfo is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs) .

HY-126531

DMAC-PDB	ADC Linker	Cancer
DMAC-PDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-114697

DSG Crosslinker Disuccinimidyl glutarate	ADC Linker	Inflammation/Immunology
DSG Crosslinker is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-118759

DSP Crosslinker 1 Publications Verification	ADC Linker	Inflammation/Immunology
DSP Crosslinker is a cleavable ADC linker, used in the synthesis of antibody-drug conjugates (ADCs) .

HY-140098

Boc-Cystamine	ADC Linker	Cancer
Boc-Cystamine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-140014

Val-Cit	ADC Linker	Cancer
Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-126349

DTSSP Crosslinker	ADC Linker	Cancer
DTSSP Crosslinker is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-101151

sulfo-SPDB	ADC Linker	Cancer
sulfo-SPDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-130111

DMAC-SPP	ADC Linker	Cancer
DMAC-SPP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-126405

SMPT	ADC Linker	Cancer
SMPT is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-W071006

PPC-NHS ester 2,5-Dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)butanoate	ADC Linker	Cancer
PPC-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133540

Maleimide-DOTA 2 Publications Verification Maleimido-mono-amide-DOTA	ADC Linker	Inflammation/Immunology Cancer
Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-133542

Dimethylamine-SPDB	ADC Linker	Cancer
Dimethylamine-SPDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133543

SPDP-sulfo	ADC Linker	Cancer
SPDP-sulfo is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133550

DMAC-SPDB	ADC Linker	Cancer
DMAC-SPDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-150043A

MDTF	ADC Linker	Cancer
MDTF is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-125305

Z-AEVD-FMK	ADC Linker	Cancer
Z-AEVD-FMK is a cleavable ADC linker for the synthesis of antibody active molecule conjugates (ADCs).

HY-160157

IM-2	Drug-Linker Conjugates for ADC	Cancer
IM-2 is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-129360

Ala-Ala-Asn-PAB	ADC Linker	Cancer
Ala-Ala-Asn-PAB is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .

HY-126496

PEG4-SPDP	ADC Linker	Cancer
PEG4-SPDP is a cleavable ADC linker used for the antibody-drug conjugates (ADCs).

HY-44221

MAC glucuronide linker-1	ADC Linker	Cancer
MAC glucuronide linker-1 is a claevable ADC linker for antibody-agent-conjugations (ADCs) .

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library

103 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 103 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Type

HY-126851

Fluorescein-DBCO	Dyes
Fluorescein-DBCO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Fluorescein-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-123687

DBCO-Sulfo-NHS ester sodium	Dyes
DBCO-Sulfo-NHS ester sodium is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Sulfo-NHS ester (sodium) is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-78921AG

Fmoc-3VVD-OH (GMP)	Fluorescent Dye
Fmoc-3VVD-OH (GMP) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-131833G

Fmoc-Gly-Gly-Phe-OH (GMP)	Fluorescent Dye
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78932G

Dap-NE hydrochloride (GMP)	Fluorescent Dye
Dap-NE hydrochloride (GMP) is Dap-NE hydrochloride (HY-78932A) produced by using GMP guidelines. Dap-NE hydrochloride is an intermediate used in the synthesis of antibody-drug conjugates (ADCs) .

HY-20336G

Mc-Val-Cit-PABC-PNP (GMP)	Fluorescent Dye
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78931G

Boc-Dap-NE (GMP)	Fluorescent Dye
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-W000423G

DBCO-amine (GMP)	Fluorescent Dye
DBCO-amine GMP is a GMP grade DBCO-amine (HY-W000423). DBCO-amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-amine is a click chemistry reagent, itcontains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-19318G

Fmoc-Val-Cit-PAB (GMP)	Fluorescent Dye
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

HY-131990G

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (GMP)	Fluorescent Dye
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-131990). MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15579G

MMAF (GMP) Monomethylauristatin F (GMP)	Fluorescent Dye
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-15579BG

MMAF sodium (GMP) Monomethylauristatin F sodium (GMP)	Fluorescent Dye
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-15578G

McMMAF (GMP) Maleimidocaproyl monomethylauristatin F (GMP)	Fluorescent Dye
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for **antibody-drug conjugates (ADC)**. McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

Cat. No.	Product Name	Type

HY-78921AG

Fmoc-3VVD-OH (GMP)	Biochemical Assay Reagents
Fmoc-3VVD-OH (GMP) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-135928

Biotin-C2-S-S-pyridine	Biochemical Assay Reagents
Biotin-C2-S-S-pyridine is a cleavable ADC linker. Biotin-C2-S-S-pyridine can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-131833G

Fmoc-Gly-Gly-Phe-OH (GMP)	Biochemical Assay Reagents
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78932G

Dap-NE hydrochloride (GMP)	Biochemical Assay Reagents
Dap-NE hydrochloride (GMP) is Dap-NE hydrochloride (HY-78932A) produced by using GMP guidelines. Dap-NE hydrochloride is an intermediate used in the synthesis of antibody-drug conjugates (ADCs) .

HY-20336G

Mc-Val-Cit-PABC-PNP (GMP)	Biochemical Assay Reagents
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78931G

Boc-Dap-NE (GMP)	Biochemical Assay Reagents
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-W000423G

DBCO-amine (GMP)	Biochemical Assay Reagents
DBCO-amine GMP is a GMP grade DBCO-amine (HY-W000423). DBCO-amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-amine is a click chemistry reagent, itcontains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-163789

Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide	Biochemical Assay Reagents
Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

HY-19318G

Fmoc-Val-Cit-PAB (GMP)	Biochemical Assay Reagents
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

HY-131990G

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (GMP)	Biochemical Assay Reagents
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-131990). MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15579G

MMAF (GMP) Monomethylauristatin F (GMP)	Biochemical Assay Reagents
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-15579BG

MMAF sodium (GMP) Monomethylauristatin F sodium (GMP)	Biochemical Assay Reagents
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-15578G

McMMAF (GMP) Maleimidocaproyl monomethylauristatin F (GMP)	Biochemical Assay Reagents
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for **antibody-drug conjugates (ADC)**. McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

Cat. No.	Product Name	Target	Research Area

HY-136432

Mc-Gly-Gly-Phe-Gly-PAB-OH Mc-GGFG-PAB-OH	ADC Linker	Cancer
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

HY-136432A

Mc-Gly-Gly-Phe-Gly-PAB-OH TFA Mc-GGFG-PAB-OH TFA	ADC Linker	Cancer
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) TFA is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

HY-P1449

Boc-Gly-Gly-Phe-Gly-OH	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate *(ADC)*.

HY-P1449A

Boc-Gly-Gly-Phe-Gly-OH TFA	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate *(ADC)*.

HY-W729138

Fmoc-D-homoArg(Et)2-OH hydrochloride	Peptides	Others
Fmoc-D-homoArg(Et)2-OH (hydrochloride) is a Fmoc-protected derivative of D-Homoarginine (HArg) that renders peptides and proteins resistant to proteolysis by trypsin. Fmoc-D-homoArg(Et)2-OH (hydrochloride) can be used as a cleavable ADC linker to synthesize antibody-drug conjugates (ADCs) .

Cat. No.	Product Name	Target	Research Area

HY-P99970

Lifastuzumab	ADC Antibody	Others
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity .

HY-P99285

Denintuzumab 1 Publications Verification hBU 12	ADC Antibody CD19	Others
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC *antibody) of antibody-drug conjugates to synthesize ADC*, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .

HY-P99352

Anetumab Anti-MSLN antibody	Mesothelin	Cancer
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor .

HY-P99042

Polatuzumab 1 Publications Verification	ADC Antibody	Cancer
Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b .

HY-P99016

Enfortumab	ADC Antibody Nectin-4	Cancer
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .

HY-P99043

Rovalpituzumab	Notch	Cancer
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine . Rovalpituzumab has activity against small cell lung cancer (SCLC) .

HY-P99205

Glembatumumab	ADC Antibody	Cancer
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .

HY-P99054

Tusamitamab	Inhibitory Antibodies	Cancer
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative) .

HY-P99740

Mirzotamab	CD276/B7-H3 ADC Antibody	Cancer
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .

HY-P99843

Datopotamab	TROP2 ADC Antibody	Cancer
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-P99229

Upifitamab 1 Publications Verification	ADC Antibody	Cancer
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for **antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b** and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer .

HY-164153

ADC Control Human IgG1-vcMMAE	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .

HY-P990786

Anti-FLT3 Antibody (AGS62P)	FLT3 ADC Antibody	Cancer
Anti-FLT3 Antibody (AGS62P) is an **ADC antibody targeting FLT3**, and can be used for acute myelogenous leukemia .

HY-164152

ADC Control Human IgG1-Deruxtecan (DAR 4)	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-164154

ADC Control Human IgG1-vcMMAF	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .

HY-P99453

Azintuxizumab	ADC Antibody	Cancer
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .

HY-141607

Indatuximab ravtansine BT-062; nBT062-DM4	Antibody-Drug Conjugates (ADCs) Bacterial	Cancer
Indatuximab ravtansine (BT-062) is an **antibody-drug conjugate (ADC) (Antibody-Drug** Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .

HY-P9980

Belantamab GSK2857914	TNF Receptor ADC Antibody	Cancer
Belantamab (GSK2857914) is a humanised IgG1 anti-BCMA (TNFRSF17) monoclonal antibody. Belantamab can be used in the synthesis of antibody-drug conjugate (ADC), Belantamab mafodotin .

HY-P990027

Izeltabart	ADC Antibody	Cancer
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as **ADC Antibody** for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .

HY-P99712

Lonigutamab hz208F2-4	IGF-1R ADC Antibody	Cancer
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody that can be used for the synthesis of antibody–agent conjugates (ADC) .

HY-P99329

Vadastuximab Anti-Human CD33 Recombinant antibody	Inhibitory Antibodies	Cancer
Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .

HY-P99684

Laprituximab J2898A	EGFR	Cancer
Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 .

HY-P99854

Disitamab RC48-0	EGFR ADC Antibody	Cancer
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)) .

HY-P99372

Lorvotuzumab Anti-NCAM1/ CD56 Reference antibody (lorvotuzumab)	ADC Antibody	Cancer
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .

HY-P99374

Naratuximab Anti-TSPAN26/CD37 Reference antibody (naratuximab)	ADC Antibody	Cancer
Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant antibody	ADC Antibody CD22	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .

HY-P99230

Pinatuzumab	Integrin CD22	Cancer
Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL) .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload .

HY-P99967

Cantuzumab	ADC Antibody	Cancer
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .

HY-P99101

Vobramitamab AEX-4089	ADC Antibody	Cancer
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. .

HY-145626

Ozuriftamab BA302	ADC Antibody	Cancer
Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis *ADC* .

HY-P99734

Mipasetamab uzoptirine ADCT-601	TAM Receptor	Cancer
Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted **antibody-drug conjugates (ADCs)*. Mipasetamab uzoptirine consists of a humanized anti-AXL antibody*, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers .

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted **antibody-drug conjugate (ADC)*. ADCT-601 has anti*-tumor activity .

HY-P99593A

Sofituzumab vedotin (solution) DMUC5754A (solution)	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .

HY-P990049

Becotatug JMT-101	EGFR	Cancer
Becotatug (JMT-101) is an IgG1 antibody targeting EGFR that can also be conjugated to Afatinib (HY-10261) and Osimertinib (HY-15772) as a synthetic ADC .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P99454

Azintuxizumab vedotin ABBV-838	Antibody-Drug Conjugates (ADCs)	Cancer
Azintuxizumab vedotin (ABBV-838) is an **antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1**, a cell-surface glycoprotein expressed on multiple myeloma cells .

HY-P99225

Mirvetuximab M9346A	Antifolate	Cancer
Mirvetuximab (M9346A) is an *anti-FOLR1* (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .

HY-145627

Ozuriftamab vedotin BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Ozuriftamab vedotin (BA3021), an **antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2)** humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .

HY-P99234

Pivekimab	Interleukin Related ADC Antibody	Cancer
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .

HY-P99233

Camidanlumab HuMax-TAC	Interleukin Related	Cancer
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia .

HY-P99682

Ladiratuzumab hLIV22	Inhibitory Antibodies	Cancer
Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an **antibody-drug conjugate (ADC)**. Ladiratuzumab can be used for research of breast cancer .

HY-P99971

Gemtuzumab	ADC Antibody	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate *(ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody*. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .

HY-P99656

Iladatuzumab MCDS0593A	ADC Antibody	Cancer
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .

HY-P99813

Patritumab deruxtecan HER3-DXd; U3-1402	Antibody-Drug Conjugates (ADCs)	Cancer
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .

HY-P99612

Farletuzumab ecteribulin MORAb-202	Antibody-Drug Conjugates (ADCs)	Cancer
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.

HY-P99881

Rolinsatamab talirine ABBV 176	Drug-Linker Conjugates for ADC	Cancer
Rolinsatamab talirine (ABBV 176) is an **antibody-drug conjugate (ADC) targeting prolactin receptor (PRLR)**. Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide linker, and SGD-1882 (HY-101127) .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted *ADC* against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-P99654

Idactamab INT-001	Inhibitory Antibodies	Cancer
Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific *ADC, targeting ASCT2 (SLC1A5)* .

HY-P99657

Iladatuzumab vedotin DCDS-0780A	Antibody-Drug Conjugates (ADCs)	Cancer
Iladatuzumab vedotin (DCDS-0780A) is an **antibody–drug conjugate (ADC)** containing humanized IgG1 anti-human CD79B monoclonal antibody (MCDS0593A; HY-P99656) conjugated to MMAE via a protease labile linker. Iladatuzumab vedotin uses novel THIOMAB technology (TDC) to consistently conjugate two MMAE molecules per antibody using engineered cysteine residues. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99352

Anetumab Anti-MSLN antibody	Classification of Application Fields Disease Research Fields Cancer	Mesothelin
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor .

HY-P99016

Enfortumab	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody Nectin-4
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .

HY-P99043

Rovalpituzumab	Classification of Application Fields Disease Research Fields Cancer	Notch
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine . Rovalpituzumab has activity against small cell lung cancer (SCLC) .

HY-P99205

Glembatumumab	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .

HY-P99054

Tusamitamab	Classification of Application Fields Disease Research Fields Cancer	Others
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative) .

HY-P99843

Datopotamab	Classification of Application Fields Disease Research Fields Cancer	TROP2 ADC Antibody
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-W034595

Eicosanedioic acid	Microorganisms Source classification	ADC Linker PROTAC Linkers
Eicosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Eicosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis

HY-117371

Hemiasterlin (-)-Hemiasterlin; Milnamide B	Alkaloids Structural Classification Classification of Application Fields Animals Marine natural products Sponge Disease Research Fields Indole Alkaloids Cancer	ADC Cytotoxin
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effcts. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-W034918

Docosanedioic acid	Structural Classification other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Plants Disease Research Fields Cancer	ADC Linker PROTAC Linkers
Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.

HY-P9980

Belantamab GSK2857914	Classification of Application Fields Disease Research Fields Cancer	TNF Receptor ADC Antibody
Belantamab (GSK2857914) is a humanised IgG1 anti-BCMA (TNFRSF17) monoclonal antibody. Belantamab can be used in the synthesis of antibody-drug conjugate (ADC), Belantamab mafodotin .

HY-P990027

Izeltabart	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as **ADC Antibody** for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .

HY-P99329

Vadastuximab Anti-Human CD33 Recombinant antibody	Classification of Application Fields Disease Research Fields Cancer	Others
Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .

HY-P99854

Disitamab RC48-0	Classification of Application Fields Disease Research Fields Cancer	EGFR ADC Antibody
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)) .

HY-P99372

Lorvotuzumab Anti-NCAM1/ CD56 Reference antibody (lorvotuzumab)	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .

HY-P99101

Vobramitamab AEX-4089	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. .

HY-P99734

Mipasetamab uzoptirine ADCT-601	Classification of Application Fields Disease Research Fields Cancer	TAM Receptor
Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted **antibody-drug conjugates (ADCs)*. Mipasetamab uzoptirine consists of a humanized anti-AXL antibody*, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers .

HY-P99225

Mirvetuximab M9346A	Classification of Application Fields Disease Research Fields Cancer	Antifolate
Mirvetuximab (M9346A) is an *anti-FOLR1* (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .

HY-P99234

Pivekimab	Classification of Application Fields Disease Research Fields Cancer	Interleukin Related ADC Antibody
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .

HY-P99682

Ladiratuzumab hLIV22	Classification of Application Fields Disease Research Fields Cancer	Others
Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an **antibody-drug conjugate (ADC)**. Ladiratuzumab can be used for research of breast cancer .

HY-P99971

Gemtuzumab	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate *(ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody*. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .

HY-W007324

Maleimide	Alkaloids Microorganisms Pyrrole Alkaloids Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	ADC Linker
Maleimide can be used for production of antibody-drug conjugate (ADC) which is used in cancer research. Maleimide also be leveraged for the preparation of fluorogenic probe, which is mainly used for the specific detection of thiol analytes .

HY-P99612

Farletuzumab ecteribulin MORAb-202	Classification of Application Fields Disease Research Fields Cancer	Antibody-Drug Conjugates (ADCs)
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.

HY-P99045

Sacituzumab	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody TROP2
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer .

HY-P9921A

Trastuzumab emtansine (solution) 2 Publications Verification Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)	Classification of Application Fields Disease Research Fields Cancer	Antibody-Drug Conjugates (ADCs) EGFR
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .

HY-131081

γ-Amanitin	Structural Classification Alkaloids Microorganisms Classification of Application Fields Other Alkaloids Source classification Disease Research Fields Cancer	DNA/RNA Synthesis ADC Cytotoxin
γ-Amanitin an ADC cytotoxin and isolated from the mushroom. γ-Amanitin inhibits RNA polymerase II and disrupts synthesis of mRNA. γ-Amanitin shows similar effects to α-Amanitin and β-Amanitin. γ-Amanitin competitively binds to monoclonal antibody (mAb), with an IC₅₀ of 163.1 ng/mL .

Cat. No.	Product Name	Chemical Structure

HY-161022S1

FL118-C3-O-C-amide-C-NH2-d5 formate
FL118-C3-O-C-amide-C-NH2-d5 formate is a deuterium labeled FL118-C3-O-C-amide-C-NH2 formate. FL118-C3-O-C-amide-C-NH2 formate is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-114816S

N-butyryl-L-Homoserine lactone-d5

N-butyryl-L-Homoserine lactone-d₅ is the deuterium labeled N-Butanoyl-L-homoserine lactone. N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm[1]. N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa[2][3].

HY-15583S

Auristatin F-d8
Auristatin F-d₈ is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .

HY-145397S

(4-NH2)-Exatecan-d5
(4-NH2)-Exatecan-d5 is a deuterated labeled (4-NH2)-Exatecan . (4-NH2)-Exatecan (compound A), a topoisomerase inhibitor, is a derivative of Exatecan. (4-NH2)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs) .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81054

	*DXd Antibody* (YA897)** Dxd, OQM5SD32BQ, UNII-OQM5SD32BQ, Exatecan derivative, Exatecan derivative for ADC	ELISA	Species independent
	DXd Antibody (YA897) is an unconjugated, mouse-derived, anti-DXd (YA897) monoclonal antibody. DXd Antibody (YA897) can be used for: ELISA expriments in species-independent background without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

ADC antibody

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Natural
Products